<DOC>
	<DOCNO>NCT01691209</DOCNO>
	<brief_summary>The study shall explore whether treatment atopic dermatitis equally effective Phoenix medical device compare standard therapy ( Hydrocortisone cream ) .</brief_summary>
	<brief_title>Efficacy/Safety Study Explore New Topical Formulation Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Male female Caucasians age 18 60 year Patients mild atopic dermatitis ( AD ) present score AD ( SCORAD ) rating 50 Skin type I IV accord Fitzpatrick Acute AD symptom assessment area ( local SCORAD â‰¥ 3 &lt; = 12 ) Baseline Acute symptom pruritus Baseline Any skin disease test area would interfere clinical assessment opinion investigator Moles , tattoo , strong pigmentation , scar test area would interfere clinical assessment Regular intake antiphlogistic drug ( example nonsteroidal antiinflammatory drug [ NSAIDs ] ) Any condition treatment might influence trial ( e.g . treatment topical antibiotic , antifungal , corticoid ) within 14 day prior screen well trial ( exception : topical treatment AD lesion test area ( example , face ) low potency steroid restrict small area ) UVtherapy use solarium within 30 day screen well trial Any alternative treatment AD ( e.g . acupuncture , kinesiology , homoeopathy ) within 30 day screen well trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Phoenix</keyword>
	<keyword>Hydrocortison</keyword>
	<keyword>mild atopic dermatitis</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>